ArticleEuropean journal of neurology2025
Olfactory Dysfunction as a Window Into the Heterogeneity of Parkinson Disease.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Greater Motor and Nonmotor Burden at Diagnosis Is Associated With Amyloid Copathology in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Olfactory Dysfunction and/or RBD for Mapping Parkinson's Disease Subtypes?European journal of neurology · 2025Article
- Olfactory Dysfunction as a Window Into the Heterogeneity of Parkinson Disease.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundWhile olfactory dysfunction is common in Parkinson disease (PD), its neural basis and clinical implications remain to be clarified. We investigated the neural substrates and clinical profiles, particularly non-motor symptoms (NMSs), associated with olfactory function.
methodsThis retrospective study included 259 drug-naïve patients with PD who underwent the Cross-Cultural Smell Identification Test (CC-SIT), comprehensive autonomic function test, neuropsychological assessments, and the Neuropsychiatric Inventory Questionnaire (NPI-Q) at diagnosis. NMS profiles were compared across olfactory groups defined by CC-SIT scores (normosmia [n = 45], hyposmia [n = 143], anosmia [n = 74]). Associations between olfaction and clinical/imaging variables were assessed using correlation and path analyses. Cox proportional hazards models were employed to evaluate the risk of developing motor complications or PD dementia according to olfactory status.
resultsCC-SIT scores correlated with Composite Autonomic Severity Scale scores (rho = -0.219, p = 0.001), NPI-Q scores (rho = -0.269, p < 0.001), and cognitive performance in memory (rho = 0.288, p < 0.001) and frontal/executive domains (rho = 0.205, p = 0.001). Dopaminergic depletion in the caudate nucleus and limbic atrophy emerged as neural substrates underlying olfactory dysfunction, mediating the association between olfaction and cognitive/neuropsychiatric symptoms. Anosmia was associated with increased risk of developing PD dementia compared to normosmia (hazard ratio [HR]: 2.579; 95% confidence intervals [CI]: 1.137-5.851) and hyposmia (HR: 2.783; 95% CI: 1.437-5.390). Anosmia was associated with higher risk of developing freezing of gait (HR: 2.571; 95% CI: 1.077-6.134) compared to normosmia.
conclusionsOlfactory dysfunction serves as a multifaceted clinical marker associated with convergent degeneration of nigrostriatal and limbic pathways, offering insights into PD phenotypic variance and its prognostic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.